Trial NCT04611802
Publication Dunkle L M, medRxiv, 2021
Primary outcome on the report: First episode of reverse transcriptase-polymerase chain reaction (RT-PCR)-confirmed symptomatic mild, moderate, or severe Covid-19 (using FDA criteria) with onset ≥7 days after the second injection

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.